Autres langues Everest Medicines Limited

Actions

1952

KYG3224E1061

Marché Fermé - Hong Kong S.E. Autres places de cotation 10:09:00 15/07/2024			Varia. 5j.	Varia. 1 janv.
19,84 ^HKD	-2,75 %		+8,06 %	-5,07 %

15/07	Everest Medicines annonce des résultats positifs pour la période de maintenance de l'essai clinique de phase 3 mené en Asie sur l'etrasimod pour le traitement de la colite ulcéreuse modérément à sévèrement active	CI
10/06	Transcript : Everest Medicines Limited Presents at Goldman Sachs 45th Annual Global Healthcare Conference, Jun-10-2024 09:20 AM

Autres langues

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

Everest Medicines Announces Positive Topline Results from Maintenance Period of Etrasimod Phase 3 Clinical Trial Conducted in Asia for the Treatment of Moderately-to-Severely Active Ulcerative Colitis	15/07
Calliditas Therapeutics Partner Offers Nefecon in China; Shares Rise	14/05
Everest Medicines Announces Commercial Launch and First Prescription for NEFECON in Mainland China	14/05
Everest Medicines Commercially Launches Kidney Disease Drug in China	14/05
Calliditas' Partner Everest Medicines Starts Commercial Launch of Nefecon in China	14/05
Everest Medicines Announces New Drug Application Approval of Velsipity® for Adults with Moderately to Severely Active Ulcerative Colitis in Macau	08/05
Everest Medicines Announces Hong Kong Department of Health Approval of Nefecon® for the Treatment for Primary IgA Nephropathy in Adult Patients	02/05
Everest Medicines' Loss Widens in 2023	25/04
Everest Medicines Limited Reports Earnings Results for the Full Year Ended December 31, 2023	28/03
Everest Medicines Announces Financial Results for Full Year Ended December 31, 2023	28/03
Everest Medicines Strengthens Management Team with Appointments of Chief Medical Officer and Chief Product Officer	18/03
Everest Medicines Strengthens Management Team with Appointments of Chief Medical Officer and Chief Product Officer	18/03
Everest Medicines to Announce Full-Year 2023 Financial Results on March 28, 2024	06/03
Everest Medicines and Kezar Life Sciences Receive IND Approval from China NMPA for PALIZADE Trial in Lupus Nephritis	27/02
Everest Medicines' Partner Pfizer Announces European Commission Approves VELSIPITY® for Patients with Moderately to Severely Active Ulcerative Colitis	22/02
Everest Medicines Licensing Partner Venatorx Pharmaceuticals Announces Publication of Positive Results from Cefepime-Taniborbactam's Phase 3 CERTAIN-1 Study in New England Journal of Medicine	21/02
Calliditas Year-end report, January - December 2023	21/02
Everest Medicines Announces Termination of Collaboration Agreements with Providence	19/02
Everest Medicines Terminates Collaboration with Canada’s Providence for mRNA COVID-19 Vaccines	19/02
Everest Medicines Limited Announces Board Changes	09/02

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Autres langues Everest Medicines Limited

Actions

1952

KYG3224E1061

Autres langues

Filtres